Health Care Archives - Page 426 of 478

1 minute read

Amgen Shares Climb As Late-Stage Lung Cancer Study Meets Primary Endpoint

August 30, 4:57 PM

Amgen (NASDAQ: AMGN) has announced top-line results from the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS (sotorasib) in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC).

AMGN

1 minute read

Despite Price Cut, RBC Capital Is Bullish On Catalent’s Long Term Targets

By Vandana Singh

August 30, 3:00 PM

RBC Capital Markets cut the price target on Catalent Inc (NYSE:CTLT) from $155 to $125 with an Outperform rating. The analyst notes…

CTLT

1 minute read

This Women Health Stock Gets Analyst Downgrade On ‘Approvability Issues, Restructuring’

By Vandana Singh

August 30, 2:56 PM

HC Wainwright has downgraded ObsEva SA (NASDAQ:OBSV) from a Buy to Neutral without a price target. Late last month, the FDA notified…

OBSV

1 minute read

Analyst Hikes Price Target, Expects Rockwell Medical To Take Steps To Improve Debt Position

By Vandana Singh

August 30, 1:27 PM

HC Wainwright has increased the price target on Rockwell Medical Inc (NASDAQ:RMTI) from $3 to $8, with a Buy rating, reflecting a 1-for-11…

RMTI

1 minute read

Y-mAbs Gets Regulatory Approval In Israel For Neuroblastoma Candidate

By Ragothaman Srinivasan

August 30, 1:08 PM

The Israeli Ministry of Health has approved Y-mAbs Therapeutics’ (NASDAQ: YMAB) lead drug DANYELZA in combination with granulocyte-macrophage colony-stimulating factor for pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

TAK

1 minute read

With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report

By Vandana Singh

August 30, 12:28 PM

Last week, Takeda Pharmaceutical Co Ltd’s (NYSE:TAK) dengue vaccine, Qdenga, was approved in Indonesia for individuals six to 45 years of age.…

GSK

1 minute read

Neurocrine Biosciences Buys UK-Based Hormone Therapy Player

By Vandana Singh

August 30, 12:23 PM

Neurocrine Biosciences Inc (NASDAQ:NBIX) has agreed to pay £48.3 million for the U.K. hormone therapy group, Diurnal Group Plc. The 27.5p share…

NBIX

1 minute read

AstraZeneca Scores Its First Global Approval For Antibody Evusheld As COVID-19 Treatment

By Vandana Singh

August 30, 12:21 PM

The regulatory authority in Japan has approved AstraZeneca plc’s (NASDAQ:AZN) Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination for…

AZN

1 minute read

Jaguar Health Seeks FDA Nod For Cholera Candidate Study

By Ragothaman Srinivasan

August 30, 10:48 AM

Jaguar Health (NASDAQ: JAGX) has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for its subsidiary Napo's NP-300 drug product candidate for the symptomatic relief of diarrhea from cholera.

JAGX

1 minute read

Outlook Therapeutics Shares Pop After Filing US Application For Its Lead Eye Disease Candidate

By Vandana Singh

August 30, 9:39 AM

Outlook Therapeutics Inc (NASDAQ:OTLK) has re-submitted its marketing application to the FDA, seeking approval for ONS-5010 for wet age-related macular degeneration…

OTLK